Valuation: BICYCL

Market Cap 269M 234M 218M 200M 378M 25.72B 384M 2.57B 1.01B 12.81B 1.01B 990M 42.94B P/E 2026 *
-1.45x
P/E 2027 * -1.68x
Enterprise Value -182M -158M -147M -135M -255M -17.35B -259M -1.73B -680M -8.64B -683M -668M -28.96B EV / Sales 2026 *
-11.1x
EV / Sales 2027 * -20.4x
Free-Float
71.44%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 269M
+2.35%+2.74%+38.10%+71.29% 56.54B
-0.21%-7.38%+27.52%+61.15% 53.6B
-2.44%+1.40%-15.61%-15.45% 22.91B
-2.85%-7.78%-9.28%+345.55% 21.37B
+2.49%-0.92%+23.57%-13.14% 20.27B
+0.79%-1.06%+33.99%-31.95% 17.56B
+0.58%-5.88%+19.40%+527.50% 14.75B
+3.41%-6.61%+162.81%+278.22% 13.53B
-5.25%-4.23%+42.32%+170.15% 13.33B
Average -0.11%-3.79%+35.87%+154.81% 25.98B
Weighted average by Cap. +0.23%-2.96%+30.79%+116.84%

Financials

2026 *2027 *
Net sales 16.31M 14.18M 13.2M 12.12M 22.89M 1.56B 23.24M 156M 61.06M 775M 61.27M 59.92M 2.6B 6.69M 5.81M 5.41M 4.97M 9.38M 639M 9.53M 63.79M 25.04M 318M 25.12M 24.57M 1.07B
Net income -186M -162M -150M -138M -261M -17.75B -265M -1.77B -696M -8.84B -698M -683M -29.63B -172M -150M -139M -128M -242M -16.44B -245M -1.64B -645M -8.19B -647M -633M -27.45B
Net Debt -451M -392M -365M -335M -633M -43.07B -643M -4.3B -1.69B -21.44B -1.69B -1.66B -71.91B -406M -353M -328M -301M -569M -38.74B -578M -3.87B -1.52B -19.29B -1.52B -1.49B -64.68B
Logo BICYCL
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-